Lantern Pharma Inc. filed a definitive additional proxy statement supplement on November 20, 2026, disclosing the resignation of President and Chief Executive Officer Panna Sharma and the appointment of Chief Financial Officer David Margrave as Interim Chief Executive Officer, effective November 16, 2026.
Key Highlights
- CEO resignation: Panna Sharma resigned as President and Chief Executive Officer of Lantern Pharma Inc., effective November 15, 2026.
- Board departure: Mr. Sharma also resigned from the Company's Board of Directors, effective November 15, 2026.
- Interim CEO named: David Margrave, current Chief Financial Officer, was appointed Interim Chief Executive Officer effective November 16, 2026.
- Board size reduced: The Board reduced the number of directors constituting the full Board from six to five, effective November 16, 2026.
- Director nominee withdrawn: Mr. Sharma's nomination for election as a director at the 2026 Annual Meeting was withdrawn; the remaining nominees will stand for election.
- Annual Meeting unchanged: The 2026 Annual Meeting of Stockholders remains scheduled for December 1, 2026 at 11:00 a.m. Eastern Time, to be held virtually.
Leadership Change at Lantern Pharma Ahead of 2026 Annual Meeting
According to the filing, Lantern Pharma Inc. (NASDAQ:LTRN), a clinical-stage oncology company based in Dallas, Texas, disclosed that Panna Sharma resigned as President and Chief Executive Officer on November 15, 2026. Mr. Sharma simultaneously resigned from the Company's Board of Directors on the same date. The proxy supplement, dated November 20, 2026, amends the definitive proxy statement originally dated October 19, 2026, which had been prepared in connection with solicitation of proxies for the 2026 Annual Meeting of Stockholders.
The filing states that the Board appointed David Margrave, the Company's current Chief Financial Officer, to serve as Interim Chief Executive Officer effective November 16, 2026, until a permanent Chief Executive Officer is appointed. According to the filing, "the Board intends to promptly commence a search for a successor." In connection with the resignation, the Board reduced its authorized size from six directors to five directors, also effective November 16, 2026, and withdrew Mr. Sharma's nomination for election at the Annual Meeting.
The filing notes that previously distributed proxy cards remain valid. Stockholders who already submitted votes marking "For All" or "For All Except" on Proposal 1 will have their votes counted for the Board's remaining nominees, but not for Mr. Sharma. The Company stated that stockholders do not need to re-submit proxies unless they wish to change their vote, and that the procedures for changing a vote or revoking a proxy remain as described in the original Proxy Statement.
What Was Disclosed
This proxy supplement from Lantern Pharma Inc. discloses the November 15, 2026 resignation of CEO and director Panna Sharma, the interim appointment of CFO David Margrave as CEO effective November 16, 2026, a reduction of the Board from six to five directors, and updated voting instructions for the December 1, 2026 Annual Meeting.



Please wait processing your request...